Program—Thursday, July 27

Plenary

Communicating Science through Comedy – Ina Park

Spotlight: New Paradigms in Sexual Health

Organizer: Bradley Stoner
Moderators: Bradley Stoner

  • SP5.1 Will Vaccines for STIs Replace Antimicrobials? –  David Lewis
  • SP5.2 STI and Youth: Addressing Root Causes– Debra Hauser
  • SP5.3 Key population-led health services –  Jagadīśa-devaśrī Dācus
  • SP5.4 Indigenous perspectives in sexual health – Margaret Kisikaw Piyesis

Symposium: Controlling Syphilis – Innovative Approaches

Organizer: Marcus Chen
Moderators: Marcus Chen and Pingyu Zhou

  • SY9.1 Doxycycline as Post-Exposure Prophylaxis (Doxy-PEP) in the STI prevention toolkit: considerations for implementation – Annie Luetkemeyer
  • SY9.2 Whole genome sequencing for Treponema pallidum: how it can be applied to the real world to better understand syphilis outbreaks – Michael Marks  
  • SY9.3 Recent studies and current understanding of the infectiousness of syphilis and novel PCR testing for Treponema pallidum including saliva – Meiping Ye
  • SY9.4 Strategies to prevent congenital syphilis – Laura Bachmann

Symposium: Advances in accessing, analysing and disseminating STI data

Organizer: Lizzi Torrone
Moderators: Lizzi Torrone and John Saunders

  • SY10.1 Applying advances made during the COVID-19 pandemic to access and disseminate STI and sexual health data – Meaghan Kall
  • ST10.2 Chat STD? Enhancing Prevention, Surveillance, and Sexual Health with AI The future is now: Applying AI and machine learning to prevent STIs and improve sexual health – Jeremy Grey 
  • SY10.3 Filling in the gaps: Collecting and triangulating data to improve STI services – Christina Schumacher 
  • SY10.4 STI data: What does the public actually want? – Rachel Kachur 

Oral Session: 2022 Mpox outbreak: Challenges and Innovations

Moderators:  Lindley Barbee and Otilia Mardh

  • O13.1 Mpox in Germany, 2022: a shift from event-linked travel-associated transmission to a large autochthonous outbreak – Klaus Jansen
  • O13.2 Case-Control Study of Risk Factors Associated with Mpox, San Francisco, CA, July–October, 2022 – Julia Janssen
  • O13.3 Clinically inapparent mpox cases among visitors of three anonymous HIV/STI testing centers in Berlin, Germany, April–October, 2022 – Uwe Koppe 
  • O13.4 Mpox among MSM in the Netherlands prior to May 2022, A Retrospective Study- Henry de Vries
  • O13.5 Characteristics of mpox positive, versus mpox negative, and mpox unsuspected clients from the Centre of Sexual Health, Public Health Service of Amsterdam, 20 May to 15 September 2022 – Henry de Vries
  • O13.6 Rectal and Pharyngeal Mpox PCR Testing of Men Who Have Sex with Men (MSM) Suggests that Rectal Testing is More Sensitive than Lesion Testing and that Most Infections Are Asymptomatic – Matthew Golden

Oral Session: Future of STI/HIV testing: Trends and Innovations

Moderators:  Uwe Koppe and Julie Dombrowski

  • O14.1 A Machine Learning Classifier to predict if Users will Return an Online Postal STI Test Kit using data captured during request processes – Efejiro Ashano
  • O14.2 Engagement in STI/HIV self-sample testing among Native Americans in Oklahoma: analysis of a community-based social media campaign – Abagail Edwards
  • O14.3 Improving syphilis screening by early detection using Treponema pallidum Transcription Mediated Amplification assay – Helene Zondag
  • O14.4 Evaluating the implementation of home-based sexual health care (Limburg4Zero) among men who have sex with men using the RE-AIM framework. – Cornelia Goense
  • O14.5The impact of HIV/STI knowledge on HIV testing and sexual behaviors among American Indians in Southern California – Tommi Gaines

Oral Session: Pathogenesis and prevention of Chlamydia trachomatis infections

Moderators: Will Geisler and Jane Hocking

  • O15.1 Chlamydia trachomatis and the risk of pelvic inflammatory disease, ectopic pregnancy, and fertility in women: final results of the Netherlands Chlamydia Cohort Study (NECCST) – Zoïe Alexiou 
  • O15.2 Oral inoculation of Chlamydia trachomatis (CT) can lead to viable rectal CT infection – Christine Khosropour
  • O15.3 Do we understand rectal chlamydia infections in women? A study including different anatomical sites, quantification and viability of Chlamydia trachomatis in two Swedish STI-clinics – Mimmi Wänn 
  • O15.4 Characterising CD4+ T cell responses to Chlamydia trachomatis in highly exposed young South African women – Rubina Bunjun 
  • O15.5 Evaluating Chlamydia trachomatis and Neisseria Gonorrhoeae screening among asymptomatic pregnant women to prevent preterm birth and low birth weight in Gaborone, Botswana. – Adriane Wynn
  • O15.6 Chlamydia trachomatis IgG seropositivity: who becomes and remains positive? – Zoïe Alexiou